An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes

References

• American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care. 2015;38:1–49.
   PubMed Web of Science ®Google Scholar
• Tropeano AI. Mechanism of diabetic complications: “therapeutic” perspectives. Ann Endocrinol (Paris). 2003;64:474–476.
   PubMedGoogle Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
   PubMed Web of Science ®Google Scholar
• Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–1772.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care. 2015;38:140–149.
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) group. JAMA. 1999;281:2005–2012.
   PubMed Web of Science ®Google Scholar
• Deacon CF, Lebovitz HE. A comparative review of DPP-4 inhibitors and sulphonylureas. Diabetes Obes Metab. 2016;18:333–347.
   PubMed Web of Science ®Google Scholar
• Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44:1126–1131.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf. 2015;14:505–524.
   PubMed Web of Science ®Google Scholar
• Avogaro A, Dardano A, de Kreutzenberg SV, et al. Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes. Diabetes Obes Metab. 2015;17:107–115.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. update to a position statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetologia. 2015;58:429–442.
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of clinical endocrinologists/American college of endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540–559.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of clinical endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement-executive summary. Endocr Pract. 2013;19:536–557.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Metformin + saxagliptin for type 2 diabetes. Expert Opin Pharmacother. 2012;13:139–146.
   PubMed Web of Science ®Google Scholar
• Teramachi H, Ohta H, Tachi T, et al. Pharmacoeconomic analysis of DPP-4 inhibitors. Pharmazie. 2013;68:909–915.
   PubMed Web of Science ®Google Scholar
• Christopher R, Covington P, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008;30:513–527.
   PubMed Web of Science ®Google Scholar
• Keating GM. Alogliptin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2015;75:777–796.
   PubMed Web of Science ®Google Scholar
• Dudkowski C, Tsai M, Liu J, et al. The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus. Eur J Clin Pharmacol. 2017;73:279–288.
   PubMed Web of Science ®Google Scholar
• Chen XW, He ZX, Zhou ZW, et al. An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015;42:1225–1238.
   PubMed Web of Science ®Google Scholar
• Huan Y, Jiang Q, Liu JL, et al. Establishment of a dipeptidyl peptidases (DPP) 8/9 expressing cell model for evaluating the selectivity of DPP4 inhibitors. J Pharmacol Toxicol Methods. 2015;71:8–12.
   PubMed Web of Science ®Google Scholar
• Seino Y, Fujita T, Hiroi S, et al. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin. 2011;27:1781–1792.
   PubMed Web of Science ®Google Scholar
• Van Raalte DH, van Genugten RE, Eliasson B, et al. The effect of alogliptin and pioglitazone combination therapy on various aspects of beta-cell function in patients with recent-onset type 2 diabetes. Eur J Endocrinol. 2014;170:565–574.
   PubMed Web of Science ®Google Scholar
• Seino Y, Hiroi S, Hirayama M, et al. Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. J Diabetes Investig. 2012;3:517–525.
   PubMed Web of Science ®Google Scholar
• Seino Y, Miyata Y, Hiroi S, et al. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. Diabetes Obes Metab. 2012;14:927–936.
   PubMed Web of Science ®Google Scholar
• Seino Y, Miyata Y, Hiroi S, et al. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. Diabetes Obes Metab. 2011;13:1028–1035.
   PubMed Web of Science ®Google Scholar
• Seino Y, Fujita T, Hiroi S, et al. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr Med Res Opin. 2011;27:21–29.
   PubMed Web of Science ®Google Scholar
• Inagaki N, Onouchi H, Maezawa H, et al. Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study. Lancet Diabetes Endocrinol. 2015;3:191–197.
   PubMed Web of Science ®Google Scholar
• Pan C, Han P, Ji Q, et al. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong. J Diabetes. 2017;9:386–395.
   PubMed Web of Science ®Google Scholar
• Mita T, Katakami N, Yoshii H, et al. Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A). Diabetes Care. 2016;39:139–148.
   PubMed Web of Science ®Google Scholar
• Masumoto N, Otsuki H, Iwakawa S, et al. Effects of alogliptin on the ratio of glycated albumin to HbA1c in patients with type 2 diabetes mellitus. Diabetol Int. 2016;8:212–217.
   PubMed Web of Science ®Google Scholar
• Del Prato S, Camisasca R, Wilson C, et al. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab. 2014;16:1239–1246.
   PubMed Web of Science ®Google Scholar
• Kaku K, Sumino S, Katou M, et al. Randomized, double-blind, phase III study to evaluate the efficacy and safety of once-daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2017;19:463–467.
   PubMed Web of Science ®Google Scholar
• Ji L, Li L, Kuang J, et al. Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial. Diabetes Obes Metab. 2017;19:754–758.
   PubMed Web of Science ®Google Scholar
• Takeshita Y, Kita Y, Kato KI, et al. Effects of metformin and alogliptin on body composition in people with type 2 diabetes. J Diabetes Investig. 2019;10:723–730.
   PubMed Web of Science ®Google Scholar
• Kishimoto S, Kinoshita Y, Matsumoto T, et al. Effects of the dipeptidyl peptidase 4 inhibitor alogliptin on blood pressure in hypertensive patients with type 2 diabetes mellitus. Am J Hypertens. 2019 May 2;hpz065. DOI:10.1093/ajh/hpz065.
   Web of Science ®Google Scholar
• McPherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62:1148–1155.
   PubMed Web of Science ®Google Scholar
• Alam S, Ghosh J, Mustafa G, et al. Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial. Hepat Med. 2018;10:23–31.
   PubMed Web of Science ®Google Scholar
• Mashitani T, Noguchi R, Okura Y, et al. Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes. Biomed Rep. 2016;4:183–187.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab. 2013;15:906–914.
   PubMed Web of Science ®Google Scholar
• Pratley RE, McCall T, Fleck PR, et al. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc. 2009;57:2011–2019.
   PubMed Web of Science ®Google Scholar
• Yabe D, Seino Y. Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation. Expert Opin Drug Saf. 2016;15:249–264.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Sherman SI, Gorelick FS, et al. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care. 2010;33:428–433.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Fleck PR, Wilson CA, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008;31:2315–2317.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010;12:648–658.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Inagaki M, Shimizu T, et al. Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study. Nephron Clin Pract. 2013;123:46–51.
   PubMed Web of Science ®Google Scholar
• Barbehenn E, Almashat S, Carome M, et al. Hepatotoxicity of alogliptin. Clin Pharmacokinet. 2014;53:1055–1056.
   PubMed Web of Science ®Google Scholar
• Itou M, Kawaguchi T, Taniguchi E, et al. Dipeptidyl peptidase-4: a key player in chronic liver disease. World J Gastroenterol. 2013;19:2298–2306.
   PubMed Web of Science ®Google Scholar
• Saad MA, Rastanawi AA, El-Yamany MF. Alogliptin abates memory injuries of hepatic encephalopathy induced by acute paracetamol intoxication via switching-off autophagy-related apoptosis. Life Sci. 2018;215:11–21.
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
   PubMed Web of Science ®Google Scholar
• Del Prato S, Camisasca R, Wilson C, et al. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab. 2014;16:1239–1246.
   PubMed Web of Science ®Google Scholar
• García M, Aranburu MA, Palacios‐Zabalza I, et al. Dipeptidyl peptidase‐IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database. J Clin Pharm Ther. 2016;41:368–370.
   PubMed Web of Science ®Google Scholar
• Takata Y, Higashiyama M, Tanaka A, et al. Alogliptin-induced bullous pemphigoid associated with HLA-DQB1*03:01: a case report. Int J Dermatol. 2019;58:e132-e133. .
   PubMed Web of Science ®Google Scholar
• Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385:2067–2076.
   PubMed Web of Science ®Google Scholar
• Marney A, Kunchakarra S, Byrne L, et al. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension. 2010;56:728–733.
   PubMed Web of Science ®Google Scholar
• Brown NJ. Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies. J Am Soc Hypertens. 2012;6:163–168.
   PubMed Web of Science ®Google Scholar
• White WB, Wilson CA, Bakris GL, et al. Angiotensin-converting enzyme inhibitor use and major cardiovascular outcomes in type 2 diabetes mellitus treated with the dipeptidyl peptidase 4 inhibitor alogliptin. Hypertension. 2016;68:606–613.
   PubMed Web of Science ®Google Scholar
• White WB, Heller SR, Cannon CP, et al. Alogliptin in patients with type 2 diabetes receiving metformin and sulfonylurea therapies in the EXAMINE trial. Am J Med. 2018;131:813–819.
   PubMed Web of Science ®Google Scholar
• NCT02856113. Phase 3 alogliptin pediatric study. cited 2018 Dec 28. Available from: https://clinicaltrials.gov/ct2/show/NCT02856113
   Google Scholar
• NCT03555565. Specified drug-use survey of alogliptin and metformin hydrochloride combination tablets “survey on long-term use in type 2 diabetes mellitus patients with renal or hepatic impairment or advanced age”. cited 2018 Dec 28. Available from: https://clinicaltrials.gov/ct2/show/NCT03555565
   Google Scholar
• Hex N, Bartlett C, Wright D, et al. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29:855–862.
   PubMed Web of Science ®Google Scholar
• Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003;46:733–749.
   PubMed Web of Science ®Google Scholar
• Nakagami T, DECODA Study Group. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia. 2004;47:385–394.
   PubMed Web of Science ®Google Scholar
• Kusunoki M, Sato D, Nakamura T, et al. The beneficial effects of the DPP-4 inhibitor alogliptin on hemoglobin A1c and serum lipids in Japanese patients with type 2 diabetes. Drug Res (Stuttg). 2016;66:18–22.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang Z, Zhao Y, et al. Alogliptin, a dipeptidyl peptidase-4 inhibitor, alleviates atrial remodeling and improves mitochondrial function and biogenesis in diabetic rabbits. J Am Heart Assoc. 2017;15(6):e005945.
   Google Scholar
• Chen W, Hartman R, Ayer R, et al. Matrix metalloproteinases inhibition provides neuroprotection against hypoxia‐ischemia in the developing brain. J Neurochem. 2009;111:726–736.
   PubMed Web of Science ®Google Scholar
• Hao FL, Han XF, Wang XL, et al. The neurovascular protective effect of alogliptin in murine MCAO model and brain endothelial cells. Biomed Pharmacother. 2018;109:181–187.
   PubMed Web of Science ®Google Scholar
• Chiazza F, Tammen H, Pintana H, et al. The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway. Cardiovasc Diabetol. 2018;17:60–73.
   PubMed Web of Science ®Google Scholar
• Li Y, Huang J, He X, et al. Postacute stromal cell-derived factor-1α expression promotes neurovascular recovery in ischemic mice. Stroke. 2014;45:1822–1829.
   PubMed Web of Science ®Google Scholar
• Zhang R, Pan X, Huang Z, et al. Osteopontin enhances the expression and activity of MMP-2 via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines. Plos One. 2011;6:e23831.
   PubMed Web of Science ®Google Scholar
• Zheng N, Chen J, Liu W, et al. Mifepristone inhibits ovarian cancer metastasis by intervening in SDF-1/CXCR4 chemokine axis. Oncotarget. 2017;8:59123–59135.
   PubMedGoogle Scholar
• Negro R, Greco EL, Greco G. Alogliptin and gliclazide similarly increase circulating endothelial progenitor cells in type 2 diabetes patients. Exp Clin Endocrinol Diabetes. 2019;127:215–219.
   PubMed Web of Science ®Google Scholar
• Tai H, Wang MY, Zhao YP, et al. The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy. Medicine (Baltimore). 2016;95:e4541.
   PubMed Web of Science ®Google Scholar
• Kodama K, Tojjar D, Yamada S, et al. Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabetes Care. 2013;36:1789–1796.
   PubMed Web of Science ®Google Scholar
• Cai Y, Zeng T, Wen Z, et al. Ethnic differences in efficacy and safety of alogliptin: a systematic review and meta-analysis. Diabetes Ther. 2018;9:177–191.
   PubMed Web of Science ®Google Scholar
• Cai X, Han X, Luo Y, et al. Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis. J Diabetes. 2015;7:347–359.
   PubMed Web of Science ®Google Scholar